NCT05118763View on ClinicalTrials.gov

Intranasal INNA-051 for Prevention of COVID-19 in Adults

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
COVID-19 Pandemic
Interventions
DRUG

INNA-051

Liquid for intranasal administration

OTHER

Placebo

Liquid for intranasal administration

Sponsors
All Listed Sponsors
lead

ENA Respiratory Pty Ltd

INDUSTRY